Designer DNA-binding Proteins Targeting Methylated DNA For Research And Therapeutic Purposes
Funder
National Health and Medical Research Council
Funding Amount
$583,444.00
Summary
A number of human genes function to suppress the onset or progression of cancer. In cancer sufferers, these genes are often switched off. The aim of this project is to engineer designer protein molecules that will be able to switch these tumor suppressor genes on again in a selective manner. Because the switching off of tumor suppressor genes is common to all forms of cancer, the new technology created in this work will potentially benefit patients suffering from any of a wide range of cancers.
DNA-binding proteins regulate gene expression to co-ordinate our development and physiology. These proteins operate by recognizing specific control sequences in target genes and turning these genes on or off. It may be possible to artificially regulate specific genes to treat certain inherited disorders. One of the most common genetic diseases worldwide is inherited haemoglobinopathy. Mutations in the adult beta haemoglobin gene cause diseases such as sickle cell anaemia and beta thalassaemia. T ....DNA-binding proteins regulate gene expression to co-ordinate our development and physiology. These proteins operate by recognizing specific control sequences in target genes and turning these genes on or off. It may be possible to artificially regulate specific genes to treat certain inherited disorders. One of the most common genetic diseases worldwide is inherited haemoglobinopathy. Mutations in the adult beta haemoglobin gene cause diseases such as sickle cell anaemia and beta thalassaemia. These diseases can be seriously debilitating or lethal and often require lifelong treatment. Current treatments (such as repeated blood transfusion and subsequent iron chelation therapy) are demanding on the patient, expensive, and in the long run can be inneffective. Proposed future treatments involve reactivating normally silent haemoglobin genes (such as foetal haemoglobin) to compensate for the absence of adult beta haemoglobin. We have been studying a DNA-binding protein termed BKLF. We have shown that BKLF turns genes off and in particular we have shown using mammalian model systems that BKLF turns off the foetal haemoglobin gene. Inhibiting BKLF action therefore becomes an important goal, as this might lead to a reactivation of foetal haemoglobin to alleviate sickle cell anaemia and beta thalassaemia. We are seeking to understand the molecular mechanisms by which BKLF silences gene expression, to identify other proteins with which it operates, and to define their activities, in an effort to identify the best ways of inhibiting BKLF's action. Ultimately, studies on defined model genes such as the haemoglobin genes should elucidate general principles of gene regulation that may be useful in controlling gene expression in additional therapeutic or experimental contexts.Read moreRead less
Designer RNA-binding Proteins For Research And Therapeutic Purposes
Funder
National Health and Medical Research Council
Funding Amount
$557,480.00
Summary
It has become clear recently that ribonucleic acids play many roles in the switching on and off of genes in humans and other organisms. These molecules play roles in a number of diseases, including HIV-AIDS, hepatitis, and a large number of inherited disorders. We propose to build a library of protein molecules that can bind specifically to a wide range of RNA targets and modulate their function. These molecules have the capacity to act as therapeutics for a wide range of diseases.
DNA-binding proteins regulate gene expression and co-ordinate normal patterns of development. We are investigating a set of DNA-binding proteins, termed the Ikaros family. These proteins are known to be important regulators of white blood cell production and mutations that interfere with Ikaros activity are associated with aggressive childhood leukaemias that are resistant to treatment. Recently, it has become apparent that Ikaros proteins also regulate genes in red blood cells. One observation ....DNA-binding proteins regulate gene expression and co-ordinate normal patterns of development. We are investigating a set of DNA-binding proteins, termed the Ikaros family. These proteins are known to be important regulators of white blood cell production and mutations that interfere with Ikaros activity are associated with aggressive childhood leukaemias that are resistant to treatment. Recently, it has become apparent that Ikaros proteins also regulate genes in red blood cells. One observation is that Ikaros plays a role in silencing the foetal haemoglobin genes. The haemoglobin genes have been extensively studied because diseases, such as beta-thalassaemia, which are caused by mutations in the adult haemoglobin genes, are among the most common genetic diseases known. One strategy to alleviate beta-thalassaemia centres around re-activating the foetal globin genes and thereby re-supplying globin to adults who have only mutant forms. In this context, the observation that Ikaros plays a role in foetal globin silencing is of considerable medical significance. We have recently identified two new regulatory proteins that are related to Ikaros and are found in red blood cells. Little is known about these proteins but they can directly bind to Ikaros and they are capable of silencing gene expression. We therefore wish to test the hypothesis that they work together with Ikaros to silence gene expression. Ultimately we expect that understanding how these proteins and Ikaros operate will suggest new strategies for re-activating the silent foetal globin genes to treat beta-thalassaemia, as well as preventing the proliferation of white blood cells carrying mutant Ikaros proteins.Read moreRead less
Great advances have been made in pharmaceutical design and discovery over the last 50 years. While drugs have traditionally been discovered using random screening of natural product libraries and chemical databases, new technologies in protein chemistry, structural and molecular biology have been adopted in efforts to speed the drug design process and increase its hit rate. In addition, our rapidly increasing knowledge of the molecular causes of many diseases provides us with many opportunities ....Great advances have been made in pharmaceutical design and discovery over the last 50 years. While drugs have traditionally been discovered using random screening of natural product libraries and chemical databases, new technologies in protein chemistry, structural and molecular biology have been adopted in efforts to speed the drug design process and increase its hit rate. In addition, our rapidly increasing knowledge of the molecular causes of many diseases provides us with many opportunities to develop therapeutics directed towards known molecular targets. Nevertheless, despite these advances, problems such as drug resistance and toxic side effects that compromise drug efficacy make it clear that there is a need for new classes of drugs with different modes of action. Because of their favourable properties, small-molecule drugs comprise by far the largest class of currently available therapeutics. However, in many cases, a drug derived from a protein may be preferable. The development of protein-based drugs is a youthful and rapidly expanding area of biotechnology, but to date, most studies have focused on targeting pathological events that occur on the outside of cells. We propose to use a combination of methods from molecular and structural biology, together with recently developed high-throughput screening techniques, to develop a generic protein drug scaffold that can be used as a template to develop therapeutics against a wide range of inappropriate interactions that may occur between molecules within cells.Read moreRead less
Obesity is associated with chronic diseases, such as diabetes and heart disease. Fat varies between individuals and can also vary across an individual's lifetime. The differences reflect genetic and physiological differences as well as different behaviours. Investigating the genes that regulate fat formation, such as the DNA-binding proteins under study here, should help us to understand and ultimately control excessive fat accumulation in order to reduce the prevalence of chronic diseases.
The Regulation Of Gene Expression During Adipogenesis
Funder
National Health and Medical Research Council
Funding Amount
$549,446.00
Summary
The body stores energy acquired from ingested food as fat droplets within storage cells termed adipocytes. The amount of fat varies between individuals and may also vary during an individual's life. The variations reflect differences in physiology, diet, and behaviour and have been the focus of intense study. Excessive accumulation of fat is a serious health problem as it is associated with conditions such as heart disease and diabetes. This grant application primarily concerns using a new line ....The body stores energy acquired from ingested food as fat droplets within storage cells termed adipocytes. The amount of fat varies between individuals and may also vary during an individual's life. The variations reflect differences in physiology, diet, and behaviour and have been the focus of intense study. Excessive accumulation of fat is a serious health problem as it is associated with conditions such as heart disease and diabetes. This grant application primarily concerns using a new line of genetically modified mice that have reduced fat. These mice lack a key gene regulatory protein that is implicated in fat accummulation and adipocyte formation. It is expected that a knowledge of the genes regulating the formation and function of fat storage cells will contribute to new strategies for controlling fat formation and will help in the prevention of diseases such as diabetes and heart disease.Read moreRead less